The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

References

• Danne T Lange K Kordonouri O New developments in the treatment of type 1 diabetes in children Arch Dis Child 2007 92 11 1015 1019 17954479
   PubMed Web of Science ®Google Scholar
• The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial Diabetes Control and Complications Trial Research Group J Pediatr 1994 125 2 177 188 8040759
   PubMed Web of Science ®Google Scholar
• White NH Cleary PA Dahms W Goldstein D Malone J Tamborlane WV Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence outcomes after the conclusion of the Diabetes Control and Complications Trial J Pediatr 2001 139 6 804 812 11743505
   PubMed Web of Science ®Google Scholar
• Dahl-Jorgensen KLJ Hanssen KF Atherosclerosis in childhood and adolescents type 1 diabetes: early disease, early treatment? Diabetologia 2005 48 8 1445 1453 15971059
   PubMed Web of Science ®Google Scholar
• Siebenhofer A Plank J Berghold A Short acting inuslin analogs versus regular human insulin in pateints with daibetes mellitus Cochrane Database Syst Rev 2004 2 CD003287 15106199
   PubMedGoogle Scholar
• Holcombe JH Zalani S Arora VK Mast CJ Comparison of insulin lispro with regular human insulin for the treatment of type 1 in adolescents Clin Ther 2002 24 4 629 638 12017407
   PubMed Web of Science ®Google Scholar
• sanofi-aventis Insulin glulisine(Apidra®) EU summary of product characteristics Availalble from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/apidra/H-557-PI-en.pdf Accessed 2010 Nov 5
   Google Scholar
• sanofi-aventis Insulin Glulisine (Apidra^®) US prescribing information Available from: http://products.sanofi-aventis.us/apidra/apidra.pdf Accessed 2010 Nov 5
   Google Scholar
• Dailey G Rosenstock J Moses R Insulin glulisine provides improved glycemic control in patients with type 2 diabetes Diabetes Care 2005 37 11 702 707
   Google Scholar
• Rayman G Profozic V Middle M Insuline glulisine imparts effective glycaemic control in patients with type 2 diabetes Diabetes Res Clin Pract 2007 76 2 304 312 17113676
   PubMed Web of Science ®Google Scholar
• Lankisch M Ferlinz K Leahy J Scherbaum WA Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regiments of insulin glulisine plus insulin glargine and oral antidiabetic drugs Diabetes Obes Metab 2008 10 12 1178 1185 19040645
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Clinical Trials Available from: http://www.clinicaltrials.gov/ Accessed 2010 Nov 5
   Google Scholar
• ApidraTM. Aventis Pharmaceuticals, Inc Insulin glulisine (rDNA origin) injection Available from: http://www.acessdata.fda.gov/drugsatfda_docs/label/2008/021629s015lbll.pdf Accessed 2010 Nov 5
   Google Scholar
• sanofi-aventis Apidra prescribing information Available from: http://products.sanofi-aventis.us/apidra/apidra.pdf Accessd 2009 Nov 5
   Google Scholar
• Heise T Heinemann L Rapid and long-acting insulin analogues as an aproach to improve insulin therapy: an evidence-based medicine assessment Curr Pharm Dis 2001 7 14 1303 1325
   PubMed Web of Science ®Google Scholar
• Poulsen C Langkjær L Worsøe C Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion Diabetes Technol Ther 2007 7 1 142 150 15738712
   PubMedGoogle Scholar
• Sluzky VTJ Klibanov AM Langer R Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces Proc Natl Acad Sci U S A 1991 88 21 9377 9381 1946348
   PubMed Web of Science ®Google Scholar
• Brange J Galenics of Insulin: The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations Berlin, Germany Springer-Verlag 1987
   Google Scholar
• Richards JP Stickelmeyer M Flora DB Chance RE Frank BH DeFelippis MR Self association properties of monomeric insulin analogs under formulation conditions Pharm Res 1998 15 9 1434 1441 9755897
   PubMed Web of Science ®Google Scholar
• Zoete V Meuwly M Karplus M Study of the insulin dimerization: binding free energy calculation and per-residue free energy decomposition Proteins 2005 61 1 79 93 16080143
   PubMed Web of Science ®Google Scholar
• Hennige AM Strack V Metzinger E Seipke G Häring HU Kellerer M Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors Diabetologica 2005 48 9 1891 1897
   Web of Science ®Google Scholar
• Danne T Becker RH Heise T Bittner C Frick AD Rave K Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes Diabetes Care 2005 28 9 2100 2105 16123473
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP Plosker GL Insulin glulisine: a review of its use in the management of diabetes mellitus Drugs 2009 69 8 1035 1057 19496630
   PubMed Web of Science ®Google Scholar
• Garg S Kelly WC Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes Expert Rev Med Devices 2008 5 2 113 123 18331174
   PubMed Web of Science ®Google Scholar
• Philotheou A Arslenian S Blatnicky L Peterkova V Souhami E Danne T Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal bolus regimen in children and adolescents with type 1 diabetes Diabetologica 2008 51 Supp 1:32 Abstract 950
   Google Scholar
• Hoogma RP Schumicki D Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes Horm Metab Res 2006 38 6 429 433 16823727
   PubMed Web of Science ®Google Scholar
• Cobry E McFann K Messer L Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes Diabetes Technol Ther 2010 12 3 173 177 20151766
   PubMed Web of Science ®Google Scholar
• Garg SK Rosenstock J Ways K Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine Endocr Pract 2005 11 1 11 17 [Erratum in Endocr Pract. 2005;11(2):145] 16033730
   PubMedGoogle Scholar
• Kawamori R Kadowaki T Ishii H Efficacy and safety of insulin glulisne in japanese patients with type 1 diabetes mellitus; using glargine as basal insulin [Abstract Number 2074-PO] Diabetes 2008 57 Suppl 1 A573
   Google Scholar
• Dreyer M Prager R Robinson A Efficacy and safety of insulin glulisine in patients with type 1 diabetes Horm Metab Res 2005 37 11 702 707 16308840
   PubMed Web of Science ®Google Scholar
• Senstius J Poulsen C Hvass A Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps Diabetes Technol Ther 2007 9 517 521 18034606
   PubMed Web of Science ®Google Scholar
• sanofi-aventis Apidra prescibing information Available from: http://products.sanofi-aventis.us/apidra/apidra.html Accessed 2009 Nov 4
   Google Scholar
• Stammberger I Seipke G Bartels T Insulin glulisine – a comprehensive preclinical evaluation Int J Toxicol 2006 25 1 25 33 16510354
   PubMed Web of Science ®Google Scholar
• Powers SW Byars KC Mitchell MJ Patton SR Standiford DA Dolan LM Parent report of mealtime behavior and parenting stress in young children with type 1 diabetes and in healthy control subjects Diabetes Care 2002 25 2 313 318 11815502
   PubMed Web of Science ®Google Scholar
• Rave K Klein O Frick AD Becker RH Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes Diabetes Care 2006 29 8 1812 1817 16873785
   PubMed Web of Science ®Google Scholar
• Kotsanos JG Vignati L Huster W Health-related quality-of-life results from multinational clinical trials of insulin lispro: Assessing benefits of a new diabetes therapy Diabetes Care 1997 20 6 948 958 9167105
   PubMed Web of Science ®Google Scholar
• Home PD Lindholm A Riis A European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial Diabet Med 2000 17 11 762 770 11131100
   PubMed Web of Science ®Google Scholar
• Bott S Tusek C Heinemann L Friberg HH Heise T The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30) Exp Clin Endocrinol Diabetes 2005 113 9 545 550 16235159
   PubMed Web of Science ®Google Scholar
• Kamoi K Miyakoshi M Maruyama R A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion Diabetes Res Clin Pract 2004 64 1 19 25 15036823
   PubMed Web of Science ®Google Scholar
• Grey M Boland E Tamborlane WV Use of lispro insulin and quality of life in adolescents on intensive therapy Diabetes Educator 1999 25 6 934 941 10711075
   PubMed Web of Science ®Google Scholar
• Deja GJ-CP Muchacka-Bianga M Insulin lispro in treatment of children and adolescents with type 1 diabetes and its effect on quality of life Diabetologia Polska 2002 9 2 52 56
   Google Scholar
• Urakami T Kawamaru T Sugihara S Japanese Study Group of Insulin Therapy for Childhood and Adolescent DiabetesA questionnaire survey on the use of quick-acting insulin analog in Japanese children and adolescents with type 1 diabetes Pediatr Int 2004 46 3 285 290 15151544
   PubMed Web of Science ®Google Scholar